1. Latest News
  2. Submit Press Release
  1. PR Home
  2. Latest News
  3. Feeds
  4. Alerts
  5. Submit Free Press Release
  6. Journalist Account
  7. PRNewswire Distribution

Ajanta Pharma gets into Top 50 league in the country

Consolidated Net up 52%, Posts 36% growth in Consolidated Revenue Company has posted 52% growth in Consolidated Net Profit for the financial year 2011-12, with Consolidated Profit after Tax at Rs.77.27crs (Rs.50.71crs).

 
PRLog - Apr. 26, 2012 - Ajanta Pharma gets into Top 50 league in the country

Consolidated Net up 52%, Posts 36% growth in Consolidated Revenue

Mumbai – (April 26, 2012) – Ajanta Pharma Limited, a specialty focused pharmaceutical formulation company, has entered in Top 50 companies in the country in the domestic market as per IMS ranking for March 2012.

Company has posted 52% growth in Consolidated Net Profit for the financial year 2011-12, with Consolidated Profit after Tax at Rs.77.27crs (Rs.50.71crs). The Consolidated revenue was up 36% at Rs.677crs (Rs.499crs).

Stand Alone Revenue for the financial year 2011-12 stood at Rs.604.27crs (Rs.458.16crs), a growth of 32% over the previous year. Profit after Tax for the year ended March 31, 2012 stood at Rs.66.49crs against Rs.46.45crs last year same period, a growth of 43%.

Performance of the fourth quarter of FY 2011-12 has also been satisfactory with revenue growth of 40% and profit growth of 35%.  Profit after Tax stood at Rs.23.60crs (Rs.17.47crs) for the quarter ended March 31, 2012. Net revenue from operations for the quarter stood at Rs.176.10crs (Rs.125.95crs).

The Company’s Board of Directors have recommended dividend @ ` 7.50 per share for the Financial Year 2011-12 and also splitting of its equity share of ` 10 each in to 2 equity shares of ` 5 each.

Company continues to aggressively execute the strategy of specialty player in the branded generic market in India and Rest of the World (ROW).  In the regulated market, company continues to build its ANDA portfolio in USA.  During the quarter, company has filed another 2 ANDA's in US taking the total ANDA's under review with the FDA to 7.  For the 2 ANDA's for which company received approval, sales shall start from Q1 of FY13.

Company’s stellar performance is testimony of its strategies being firmly rooted in ground realities of the dynamic market place. Company is moving ahead, making progress, steadily with a strong determination, to have stronger and wider foundation for the continued growth of the organisation.

Company is gaining grounds in domestic market with improved ranking, enhancing depth in export ROW markets and making the beginning in USA with our first product being available in the US market from coming quarter onwards.

Company’s geographic spread, wonderful product portfolio, sound R&D and manufacturing excellence provide it a unique position, which not only balances its risks but also provide it with sound platform for sustained growth in coming years.

About Ajanta pharma

Ajanta Pharma is a speciality pharmaceutical formulation company, having leading brands in the therapeutic segments of Ophthalmology, Dermatology and Cardiology. Many of the company’s products are first of its kind and are leading in their sub therapeutic segments.  Company exports its products to more than 25 countries and established strong brand equity in these markets. For last 10 years, company’s consolidated performance has been excellent with CAGR of 22% in sales and 46% in net profit.

Ajanta Pharma has its State of the Art R&D centre located at Mumbai, with more than 200 scientists working for formulation development.  The company has world class manufacturing facilities - four located in India and one at Mauritius.  One of the manufacturing facilities at Aurangabad is approved by US FDA, UK MHRA and World health organisation (WHO), apart from having the approval from FDA of many other countries.

--- End ---

Click to Share

Contact Email:
***@ajantapharma.com Email Verified
Source:Company
Country:India
Industry:Pharmaceutical
Tags:pharma, result, update, growth, profit
Shortcut:prlog.org/11859758
Disclaimer:   Issuers of the press releases are solely responsible for the content of their press releases. PRLog can't be held liable for the content posted by others.   Report Abuse

Latest Press Releases By “

More...

Trending News...



  1. SiteMap
  2. Privacy Policy
  3. Terms of Service
  4. Copyright Notice
  5. About
  6. Advertise
Like PRLog?
9K2K1K
Click to Share